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ABSTRACT 
 
During the past 15 years, emergence and dissemination of third-generation cephalosporins 
resistance in nosocomial Enterobacteriaceae became a serious problem worldwide, due to 
the production of extended-spectrum-β-lactamases (ESBLs). The aim of this study was to 
investigate among the presence of ESBL-producing enterobacteria among Portuguese 
clinical isolates nearby Spain, to investigate the antimicrobial susceptibility patterns and to 
compare the two countries. The β-lactamases genes, blaTEM, blaSHV and blaCTX-M were 
detected by molecular methods. Among the ESBL-producing isolates it was found 
extraordinary levels (98.9%) of resistance to the fourth-generation cephalosporin Cefepime. 
These findings point to the need of reevaluate the definition of ESBL. 
 
Nos últimos15 anos, a emergência e disseminação da resistência das enterobactérias 
nosocomiais às cefalosporinas de teceira geração devido à produção de β-lactamases de 
espectro ampliado (ESBL) tem-se tornado uma preocupação a nível mundial. O objectivo 
deste estudo é determinar a presença de ESBL em isolados clínicos de enterobactérias, o 
perfil de susceptibilidade aos antimicrobianos e comparar a situação portuguesa com a 
espanhola. Os genes blaTEM, blaSHV e blaCTX-M das β-lactamases foram detectados por 
métodos moleculares. Nas estirpes portuguesas produtoras de ESBL foram detectados 
níveis preocupantes de resistência à Cefepima (4ª geração), 98,9%, levando-nos a 
questionar sobre a necessidade de redefinir ESBL.    
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1. INTRODUCTION 
Extended-spectrum β-lactamases (ESBLs) are enzymes that confer resistance to Aztreonam, Cefotaxime, 
Ceftazidime, and related oxyimino-β-lactams as well as to older penicillins and cephalosporins but are 
inhibited by Clavulanic acid (Bush et al., 1995). ESBL-producing Enterobacteriaceae were first reported 
in Europe in the 1980s and have since become a worldwide problem (Paterson and Bonomo, 2005). This 
has resulted in increased morbidity, mortality and cost in treating the infections they cause (Paterson et 
al., 2001). The first ESBL were mutants of the TEM and SHV plasmid-mediated penicillinases with one 
or more aminoacid substitutions. The mutations conferred resistance to all oxyimino-cephalosporins but 
not α-methoxy-cephalosporins (cephamycins) or carbapenems by causing enlargement of ESBL active 
site, which allowed the deflection of the oxyimino group diminishing the attack efficiency on the β-
lactam ring (Livermore and Woodford, 2006). TEM and SHV present to date over 200 members known 
(http://www.lahey.org/studies). Another ESBL group, include the CTX-M enzymes, that are organized in 
five major CTX-M groups: 1, 2, 8, 9, and 25 (Bonnet, 2004). The CTX-M comprise a rapidly growing 
family distributed both over wide geographic areas among a wide range of bacteria of clinical 
significance and are becoming more prevalent than its ancestors TEM and SHV in several countries in 
Europe (Livermore et al., 2009). Several studies have been reported in Iberian Peninsula describing the 
genetic and clinical environments of ESBL occurrence (Rodríguez-Baño et al., 2004; Hernández et al., 
2005; Machado et al., 2006; Mendonça et al., 2007, Amador et al. 2009, Fernandes et al. 2009). 
Here we report the molecular and antimicrobial susceptibility profile of the ESBLs found in the 
Portuguese occidental cost in the boundaries between the two countries, Portugal and Spain. For this task 
it were used methods of molecular typing that have been developed for the identification of the β-
lactamases bla genes in Enterobacteriaceae bacteria from clinical hospitalized and non-hospitalized 
patients for a period of two years.  
2. MATERIALS AND METHODS 
2.1. Bacterial strains, identification and susceptibility 
A total of 7529 clinical strains were included in the study. All isolates were gently provided from Clinical 
Pathology Laboratories and belong to patients samples recovered from September 2007 to August 2009 in 
the northern occidental coast of Portuguese territory (Minho). This area comprises several populations of 
the northern of Portugal and some at the boundaries with Galicia, Spain. Bacteria identification and 
preliminary antimicrobial susceptibility were determined in accordance with the guidelines of the Clinical 
and Laboratory Standards Institute (2007). ESBL production was confirmed by the elipsoid method, 
using two E-test Strips (AB Biodisk, Sweden). Each strip contained several concentrations of a third 
generation cephalosporin, Ceftazidime (TZ) and Cefotaxime (CT) alone and with Clavulanic acid (TZL, 
CTL). The ESBL strip contained CT gradient at one end (0.25-16 mg/L) and a gradient of Cefotaxime 
(0.016-1 mg/L) plus 4 mg/L of Clavulanic acid (L), an inhibitor of ESBL, at the other end (CTL). The 
other ESBL strip contained TZ gradient at one end (0.5-32 mg/L) and a gradient of TZ (0.064-4 mg/mL) 
plus L (4 mg/L) at other end (TZL). According to manufacturer an ESBL is considered present whenever 
the E-test attends at least 8-fold MIC decrease on TZL or CTL.  
2.2. Conjugation experiments 
Transmissibility of resistance was test by matting clinical isolates to F- strains of azide-resistant E. coli 
J53 AziR on trypticase soy broth (TSB) according with Amador  (2010). 
2.3. Analytical isoelectric focusing (IEF) 
Crude preparations of β-lactamases from clinical strains transconjugants were obtained by sonicating the 
cells in phosphate buffer, pH 7.0 as described in previously by Fernandes & Prudêncio (2010). Briefly 
crude extracts were concentrated and crude protein concentrated extract was added to a nitrocefin 
solution. The sample run in a IEF mini-gels, pH 3 to 10 for 30 min using both anode and cathode 
electrode buffers. β-lactamases isoelectric point (pI) was determined by pouring molten 3% agarose 
containing nitrocefin over the gel and comparing the bands to standards run on the same gel. The β-
lactamase standards used were extracts of strains containing TEM-1, pI 5.4, SHV-5, pI 8.2 and CTX-M-
14, pI 8.1. 
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2.4. Genetic molecular characterization of bla genes and typing 
A single colony of each transconjugant was left to grow for 16h on MacConkey agar and was placed in 
200 µL sterile water in a 1.5 mL microtube. Each tube was heated in a microwave oven at 600–700 W for 
2 min to burst the cells and release their DNA. PCR was performed according to Fernandes et al. (2010). 
The recovered bands from agarose were subcloned for further sequencing. The nucleotide sequences of 
both ends of the insert were determined with M13 sequencing primers specific for the cloning vector 
(Naiemi NA et al., 2005). ERIC profiles were analyzed with software, FPQuest™ version 4.5, 
Fingerprinting II (Bio-Rad Laboratories, CA, USA).
 
3. RESULTS 
The prevalence of ESBL-producing strains in the north Portuguese territory was 2.6% (n=193). The most 
frequent ESBL-producing organism was E. coli (67.9%, n=131), followed by K.  pneumoniae (30.6%, 
n=59), K. oxytoca (0,5%, n=1), E. aerogenes (0,5%, n=1) and C. freundii (0,5%, n=1). The ESBL-
producing strains were isolated from urine (n=127), sputum (n=42), bronchoalveolar lavage (n=14), blood 
(n=7) and ascitic fluid (n=3). The types of ESBL detected in the present study appear in the table 1 and 
were in percents as follows. TEM types were detected in 40.9%, CTX-M types in 37.3% and SHV types 
in 23.3%. Several isolates harboring also broad-spectrum β-lactamases, such as TEM-1 (pI=5.4), TEM-2 
(pI=5.6) and SHV-1 (pI 7.6) types, but are not presented in this study.  
Table 1:  Characterization ESBL-producing strains 
ESBL IEF (pI) 
Microorganism 
(no. of isolates) 
Conju-
gation 
(% 
positive) 
Resistance phenotype (% Non-susceptible: I+R) 
ERIC types 
patterns β-lactams Non β-lactams 
CEP FOX CIP GEN Bactrim 
TEM-4 5.9 E. coli (2) 
K. pneumoniae (1) 
 
100 
100 
100 
100 
 
50 
0 
100 
100 
50 
100 
100 
0 
A 
L 
TEM-10 6.0 E. coli (8) 
 
87.5 100 25 87,5 0 75 B,D,H 
TEM-24 6.5 E. coli (12) 
K. pneumoniae (11) 
K. oxytoca (1) 
E. aerogenes (1) 
 
83.3 
81.8 
100 
100 
100 
100 
100 
100 
50 
20 
100 
0 
75 
72.7 
100 
0 
8.3 
50 
0 
100 
8.3 
63.6 
100 
100 
C,G,H,I 
K,L,O 
n.a. 
n.a. 
TEM-52 6.0 E. coli (27) 
K. pneumoniae (12) 
 
81.4 
100 
100 
100 
 
36.4 
8.4 
84.6 
91.6 
53.8 
83.3 
42.3 
33.3 
A,B,E,F,J  
N,O 
TEM-116 5.4 E. coli (n=4) 
 
100 
 
100 
 
50 
 
75 75 0 F 
SHV-2 7.6 K. pneumoniae (3) 
E. coli (1) 
 
100 
100 
33.3 
0 
33.3 
0 
66.7 
100 
66.7 
100 
100 
100 
L 
A 
SHV-5 8.2 K. pneumoniae (11) 
E. coli (6) 
 
72.7 
83.3 
100 
100 
27.3 
66.7 
63.6 
100 
72.7 
100 
27.3 
0 
L,N 
SHV-12 8.2 K. pneumoniae (18) 
E. coli (6) 
 
83.3 
100 
100 
100 
27.7 
33.3 
61.1 
100 
94.4 
100 
77.8 
66.7 
K,M,N,O 
C,D,E 
CTX-M-1 6.3 E. coli (1) 
 
100 100 25 100 100 0 E 
CTX-M-3 8.4 C. freundii (1) 
 
0 100 0 0 100 0 n.a. 
CTX-M-9 8.1 E. coli (26) 
 
92.3 100 26.9 96.2 84.6 3.8 A,C,D,G,I,J 
CTX-M-14 8.1 E. coli (16) 
 
68.8 100 12.5 100 75 0 D,F,H, J 
CTX-M-15 8.6 E. coli (21) 
K. pneumoniae (3) 
 
85.7 
100 
100 
100 
38.1 
100 
100 
100 
90.5 
100 
14.3 
100 
A,C,E,I,J 
N 
CTX-M-32 
 
9.0 E. coli (1) 
 
100 100 0 100 100 0 D 
ESBL: extended-spectrum β-lactamase; IEF: isoelectric focusing; pI: isoelectric point; I: Intermediate; R: Resistant; n.a.: Not 
applicable. Antimicrobials: CEP: Cefepime; FOX: Cefoxitin; CIP: Ciprofloxacin; Gen: Gentamicin; Bactrim: combination of 
Trimethoprim and Sulfamethoxazole; 
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MIC tests shown that isolates producing TEM, SHV and CTX-M ESBL types also appears in Table 1and 
were mostly resistant to Cefepime (98.9%) and susceptible to Carbapenems (100%) and Amikacin 
(99.5%).  Nevertheless, some SHV-producing  strains, shown an important reduced susceptibility to other 
member of Aminoglycosides, namely Gentamicin (11.1%). ESBL-producing strains from this sample also 
present reduced susceptibility to Quinolones (14.6%) in the generality, being more conspicuous in the 
members of the CTX-M family (1.9%) rather than TEM and SHV members (19.2% and 27.9% 
respectively).  
Regarding interspecific genetic similarity, it was observed a high genetic diversity. It was possible to 
define 10 clusters for E. coli based on Pearson’s correlation coefficient in PCR-ERIC based profile (data 
not shown). For K. pneumoniae it was defined 5 different clusters for the PCR-ERIC (data not shown). 
4. DISCUSSION 
As reported in previous Portuguese (Machado et al., 2006; Mendonça et al., 2007; Costa et al., 2004, 
Costa et al., 2008, Fernandes et al., 2008, Amador et al., 2009, Fernandes et al., 2009, Amador et al., 
2010, Fernandes & Prudêncio 2010), Spanish (Brinãs et al., 2002; Coque et al., 2008; Hernández, et al., 
2005; Miró et al., 2005) and other European (Livermore et al., 2009) studies E. coli and K. pneumonia are 
the species where ESBL is the most frequently identified. In this study E. coli were the most frequent 
(n=131) organism expressing ESBL phenotypes, more than two fold of the K. pneumonia (n=59), the 
second most frequent. 
TEM-52 and TEM-24 were the most frequent TEM types, 20.2% (n=39) and 12.9% (n=25) respectively. 
Members of the TEM-10 (n=8) and TEM-116 (n=4) were also detected. Within CTX-M family, the CTX-
M-9 group is more prevalent than the CTX-M-1 group (58.3% against 41.6%). CTX-M-9 group was 
represented by CTX-M-9 (n=26, 36.1%) and CTX-M-14 (n=16, 22.2%). In the CTX-M-1 group, CTX-
M-15 was most frequent type (n=24, 33.3%), followed by CTX-M-1 (n=4, 5.5%), CTX-M-3 (n=1, 1.3%) 
and CTX-M-32 (n=1, 1.3%). The SHV enzymes occurred only in 23.3% of all ESBL- producing 
organisms. Within this type, the most frequent was the SHV-12 (n=24, 53.3%), followed by SHV-5 
(n=17, 37.8%) and finally SHV-2 (n=4, 8.8%). Some isolates co-produced more than one ESBL type: 
TEM-52/CTX-M-14 (n=1), TEM-116/CTX-M-14 (n=1) and TEM-116/CTX-M-15 (n=1).  
Regarding the high diversity ESBL types obtained in our study, we find interesting to compare with 
neighbor regions, such as Douro Litoral located at south of Minho, Trás-os-Montes e Alto Douro, eastern 
and the Spanish province of Galiza, located at north of Minho (Figure 1). From this comparison and 
regarding to TEM types ESBL, TEM-10, TEM-20, TEM-26 and TEM-116 in E. coli and TEM-4 in K. 
pneumoniae were present only in this region but have been reported in other locations of Iberian 
Peninsula. Isolates of E. coli producing SHV-2 and SHV-5 were also found only in this region. 
Nevertheless, it has been described previously in the Iberian Peninsula (Hernandez et al., 2005). 
Regarding CTX-M types, it seems that CTX-M-14 is widespread among the northwestern Iberian 
Peninsula. K. pneumoniae harboring a CTX-M-15 was described for the first time in Portugal in 2005 
(Conceição et al., 2005)  in Lisbon area but it is also found in the north of Portugal in this study and 
Douro (Machado et al., 2006). Other ESBL-producing species non-E.coli and non-K. pneumonia were 
also found. It has been the first time that an E. aerogenes is described in this country as producer of a 
TEM-24 and the first time that is found a C. freundii as a producer of a CTX-M-32. 
In what concerns to the clonally studies, it seems clear the high genetic diversity among the strains in 
study. Nevertheless, some considerations are needed. K cluster for K. pneumoniae was represented by 
TEM-24 producing members only. Nevertheless, it may be due to a coincidence. The two strains 
presenting the tightest resemblance were only 74% genetically related. The antibiogram for the four 
strains were also different between all them (data not shown). Moreover, they belong to four patients, two 
males and two females, interned in different clinical services. In the opposite situation, the CTX-M-15 
producing K. pneumoniae, bellowing to N cluster, presented the exactly antibiogram profile and the strain 
less related to the other two, shared a 93% of genetic similarity and the most related two of them, 
presented a 98% of genetic similarity. The patients, three females with ages between 76 and 86 years old, 
shared the same clinical service, Medicine Females, during the same period, from October to November 
2007. 
Cefepime presents, in this study a surprisingly low activity against ESBL-producing microrganisms. In 
our sample only two K. pneumoniae harboring SHV-2 ESBL were susceptible to Cefepime. All the other 
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clinical isolates, 98.9% (n=191) expressing the ESBL phenotype were resistant to Cefepime. It seems 
interesting that a recent study showed that Cefepime was successfully administrated to three patients (two 
females and one male) with ages between 47 and 87 years old carrying a gram-negative ESBL positive 
strain (Bhavnani et al., 2006). Nevertheless Other studies worldwide start to describe the emergence of 
high resistance among ESBL gram-negative producers (Grover et al., 2006; Sader et al., 2007). 
 
 
Figure 1. Occurrence of ESBL-TEM, ESBL-SHV and ESBL-CTX-M type in the north of Portugal. The 
present study territory, Minho (M), is represented at the map in white. Other regions either from Portugal 
or Spain, are represented with different gray tones. Data was collected from this study and from several 
studies in these two countries namely by Amador et al. (2009,2010), Briñas et al. (2002,2005), Coque et 
al. (2000,2008),  Costa et al. (2002,2008,2009), Conceição et al. (2005), Fernandes et al. (2008,2009), 
Fernandes & Prudêncio (2010), Fernández et al. (2007), Hernández et al. (2005), Machado et al. (2006) 
and Mendonça et al. (2007). 
In summary, this work showed the high diversity of ESBL-enzymes occurring in Portugal. In this 
country, the most prevalent type is still the TEM-type but CTX-M is growing rapidly. The ERIC analysis 
shows to be efficient in the clonally relationships between the different Enterobacteriaceae isolates, and it 
was possible to detect an episode of nosocomial infection. Nevertheless, it was obtained indistinguishable 
patterns among ESBL-producing strains. The emergence of ESBL producers resistant to Cefepime in 
Portugal is a matter of concern. We believe that the uncontrolled use of cephalosporins may have an 
important role in the acquisition of resistance mechanisms, specially the production of ESBL enzymes. It 
seems to be urgent the establishment of policies to monitor drug delivery in hospital and ambulatory 
pharmacies and the implementation of public health defense strategies towards health promotion and drug 
resistance prevention. 
  
 6
5. REFERENCES  
Amador, P., Fernandes, R., Prudêncio, C., & Brito, L. (2009). Resistance to β-lactams in bacteria isolated 
from different types of Portuguese cheese. Int J Mol Sci; 10:1538–51. 
Amador, P., Fernandes, R., Brito, L., & Prudêncio, C. (2010). Antibiotic resistance in enterobacteriaceae 
isolated from Portuguese deli meats. J Food Safety (In Press). 
Bhavnani, S.M., Ambrose, P.G., Craig, W.A., Dudley, M.N., Jones, R.N. (2006). Outcomes evaluation of 
patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by 
CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn 
Microbiol Infect Dis 54:231–6. 
Bonnet, R. (2004) Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob 
Agents Chemother 48:1-14.  
Briñas, L., Zarazaga, M., Sáenz, Y., Ruiz-Larrea, F., & Torres C. (2002). β-lactamases in Ampicillin-
Resistant Escherichia coli Isolates from Foods, Humans, and Healthy Animals. Antimicrob Agents 
Chemother 2002; 46:3156–63. 
Briñas, L., Lantero, M., de Diego, I., Alvarez, M., Zarazaga, M., & Torres C. (2005). Mechanisms of 
resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish 
hospital. J  Antimicrob Chemother 56:1107–10. 
Bush, K., Jacoby, G.A., Medeiros, A.A. (1995) A functional classification scheme for β-lactamases and 
its correlation with molecular structure. Antimicrob Agents Chemother 39: 1211–33. 
Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for 
bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards 
Institute, Wayne, PA, 2007. 
Conceição, T., Brízio, A., Duarte, A., Lito, L.M., Cristino, J.M., & Salgado, M.J (2005). First description 
of CTX-M-15-producing K. pneumoniae in Portugal. Antimicrob Agents Chemother 49:477–8. 
Coque, T.M., Oliver A, Pérez-Díaz JC, Baquero F, Cantón R. Genes Encoding TEM-4, SHV-2, and 
CTX-M-10 extended-spectrum β-lactamases are carried by multiple Klebsiella pneumoniae clones in 
a cingle hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 2000; 46:500–10. 
Coque, T.M., Novais A., Carattoli, A., Poirel, L., Pitout, J., & Peixe, L. (2008) Dissemination of clonally 
related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect 
Dis 14:195–200. 
Costa, D., Poeta, P., Briñas, L., Sáenz, Y., Rodrigues, J., & Torres, C. (2004). Detection of CTX-M-1 and 
TEM-52 β-lactamases in Escherichia coli strains from healthy pets in Portugal. J Antimicrob 
Chemother 2004; 54:960–1 
Costa, D., Poeta, P., Sáenz, Y., Coelho, A.C., Matos, M., & Vinué, L. (2008) Prevalence of antimicrobial 
resistance and resistance genes in faecal Escherichia coli isolates recovered from healthy pets. Vet 
Microbiol 127:97–105. 
Costa, D., Vinué, L., Poeta, P., Coelho, A.C., Matos, M., & Sáenz, Y. (2009). Prevalence of extended-
spectrum β-lactamase-producing Escherichia coli isolates in faecal samples of broilers. Vet Microbiol 
138:339–44.  
Fernandes, R., Vieira, M., Ferraz, R., & Prudêncio, C. (2008). Bloodstream infections caused by 
multidrug-resistant Enterobacteriaceae: report from two Portuguese hospitals. J Hosp Infect 70: 93-5. 
 7
Fernandes, R., Gestoso, A., Freitas, J.M., Santos, P., & Prudêncio, C. (2009) High resistance to fourth-
generation cephalosporins among clinical isolates of Enterobacteriaceae producing extended-
spectrum β-lactamases isolated in Portugal. Int J Antimicrob Agents 33:184–5.  
Fernandes, R., & Prudêncio, C. (2010). Post-surgical wound infections involving Enterobacteriaceae with 
reduced susceptibility to β-lactams in two Portuguese hospitals. Int Wound J 2010 (In Press). 
Fernández, A., Gil, E., Cartelle, M., Pérez, A., Beceiro, A., & Mallo, S. (2007). Interspecies spread of 
CTX-M-32 extended-spectrum β-lactamase and the role of the insertion sequence IS1 in down-
regulating bla CTX-M gene expression. J Antimicrob Chemother 59:841–7. 
Grover, S.S., Sharma, M., Chattopadhya, D., Kapoor, H., & Pasha, S.T. (2006).  Singh G. Phenotypic and 
genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: 
Emergence of high resistance against cefepime, the fourth generation cephalosporin. J Infect 53:279–
88. 
Hernández, J.R., Martínez-Martínez, L., Cantón, R., Coque, T.M., &Pascual, A. (2005). Nationwide 
Study of Escherichia coli and K. pneumoniae producing extended-spectrum β-lactamases in Spain. 
Antimicrob Agents Chemother 49:2122–25. 
Livermore, D.M., Cantón, R., Gniadkowski, M., Nordmann, P., Rossolini, G.M., & Arlet, G. (2007). 
CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59:65–74. 
Livermore, D.M., & Woodford, N. (2006). The β-lactamase threat in Enterobacteriaceae, Pseudomonas 
and Acinetobacter. Trends Microbiol 14:413–20.  
Livermore, D.M. (2009) β-lactamases – the threat renews. Curr Protein Pept Sci. 10:397–400. 
Machado, E., Coque, T.M., Cantón, R., Baquero, F., Sousa, J.C., & Peixe, L. (2006). Dissemination in 
Portugal of CTX-M-15-, OXA-1-, and TEM-1-producing Enterobacteriaceae strains containing the 
aac(6')-Ib-cr gene, which encodes an aminoglycoside- and fluoroquinolone-modifying enzyme. 
Antimicrob Agents Chemother 50:3220–1. 
Mendonça, N., Leitão, J., Manageiro, V., Ferreira, E., & Caniça, M. (2007). Spread of extended-spectrum 
β-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial 
environments in Portugal. Antimicrob Agents Chemother 51:1946–55. 
Miró, E., Mirelis, B., Navarro, F., Rivera, A., Mesa, R.J., & Roig, M.C.(2005). Surveillance of extended-
spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob 
Chemother 56:1152–5.  
Naiemi, N.A., Duim, B., Savelkoul, P.H., Spanjaard, L., de Jonge, E., & Bart, A. (2005). Widespread 
transfer of resistance genes between bacterial species in an intensive care unit: implications for 
hospital epidemiology. J Clin Microbiol 43:4862-4. 
Paterson, D.L., & Bonomo, R.A. (2005). Extended-spectrum β-lactamases: a Clinical update. Clin 
Microbiol Vet 18:657–86 
Paterson, D.L., Ko, W.C., Von Gottberg, A., Casellas, J.M., Mulazimoglu, L., & Klugman K.P., et al. 
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms 
producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory. J 
Clin Microbiol 2001; 39:2206–12. 
Rodríguez-Baño, J., Navarro, M.D., Romero, L., Martinez-Martinez, L., Muniain, M.A., Perea, E.J. 
(2004). Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-
producing Escherichia coli in non-hospitalized patients. J Clin Microbiol 42:1089–94. 
Sader, H.S., Hsiung, A., Fritsche, T.R., & Jones, R.N. (2007) Comparative activities of cefepime and 
piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with 
an ESBL phenotype. Diagn Microbiol Infect Dis 57:341–4. 
